

Drug Pricing: A Perspective

Victor Garcia

Accordingly drug pricing revenue was generating highly. In past one year drugs and sanitizers got sold very effectively. In the past 10 years in worldwide so many drugs were established due to many diseases was taking birth.

So, many pharmaceutical companies were introducing newly established drugs with lowest prices and highest prices. Prices are based on drug and the drug established company. Drugs were continually publishing with various of sizes, quality, design, coloring, quantity in mg's etc., For example there are so many drugs for the fever in the market but each year 10,000+ drugs were invented on fever and releasing in the market.

From only the US in 2016 brought more than 328\$ billion in prescription drugs had sold, out of the prescription also the so many drugs was sold. Will report here on drug production, trafficking and transit routes found in the Asia Pacific region. Various countries have sale their drugs to improve and decrease their related to pharmaceutical prices and transactions, more than middle class patients' out-of-pocket costs, and ensure accountability to taxpayer

more than middle class patients' out-of-pocket costs, and ensure accountability to taxpayers. Most recently, House Speaker Nancy Pelosi, D-Calif., issued a proposal to negotiate prices annually for the top 250 most expensive drugs on the market that don't have at least two competitors. The proposal also includes a \$2,000 out-of-pocket cap on prescription drugs for Medicare beneficiaries and the disabled. Now a days more drugs are releasing with high quality and high prices

Value-based payments

The shift toward value-based payments means pharmaceutical companies must deliver products that demonstrate real, measurable value. This requires a new mindset in terms of how these companies market and price their products.

Data analytics

There are so many efforts are in refine the use and exchange of health data so pharmacy companies can glean actionable insights. Technology and data will be a key part of success in the market, and pharmacy companies must choose their suppliers or partners wisely.

Correspondence to: Victor Garcia, Assistant Professor, Department of Pharmacology, Medical College, Basic Science Building, United States; Email: Victor_Garcia02@nymc.edu

Received: January 06, 2021, **Accepted:** January 13, 2021, **Published** January 20, 2021

Citation Victor Garcia (2021) Editor Note on Pharmacist Helps in COVID time. J Appl Pharm 13: 274

Copyright: © 2021 Victor Garcia. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.